2. Diokno A.C., Estanol M.V.C., Ibrahim I.A. et al. Prevalence of urinary incontinence in community dwelling men: a cross sectional nationwide epidemiological survey. Int Urol Nephrol. 2007;39:129–136.

3. Wu J.M., Vaughan C.P., Goode P.S., et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstetr Gynecol. 2014;123:141–148. Doi: 10.1097 / AOG.0000000000000057

4. Stewart W.F., VanRooyen J.B., Cundiff G.W. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003;20:327–336.

5. Irwin D.E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006;50(6):1306–1314.

6. Kogan M.I., Zachoval R., Ozyurt C., Schäfer T., Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014t;30(10):2119–2130. Doi: 10.1185/03007995.2014.934794. Epub 2014 Jun 30.

7. Astellas Pharma. Data on file. (MIR/12/0007/EU).

8. www.123rf.com/photo_34187693_mirabegron-overactive-bladder-treatment-drug-molecule-atoms-are-represented-as-spheres-with-conventi.html.

9. Ahlquist R.P. A study of the adrenotropic receptors. Am J Physiol 1948;153:586–600.

10. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G. Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597–598.

11. Nergårdh A., Boréus L.O., Naglo A.S. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol (Copenh). 1977;40:14–21.

12. Emorine L.J., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A.D. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989;245:1118–1121.

13. Muzzin P., Revelli J.P., Kuhne F., Gocayne J.D., McCombie W.R., Venter J.C.,Giacobino J.P., Fraser C.M. An adipose tissue-specific beta-adrenergic receptor. Molecular cloning and down-regulation in obesity. J Biol Chem. 1991;266(35):24053–2458.

14. Department of Health Therapeutic Goods Administration: Australian Public Assessment Report for Mirabegron, (2014).

15. Elsukova E.I., Medvedev L.N. Physiology. The new type of thermogenic adipocytes: provenance, properties, functions. V mire nauchnyh otkrytij. 2016;8(80):97–127. Doi: 10.12731/wsd-2016-8-97-127. Russian (Елсукова Е.И., Медведев Л.Н. Физиология. Новый тип термогенных адипоцитов: происхождение, свойства, функции. В мире научных открытий. 2016;№8(80):97–127. DOI: 10.12731/wsd-2016-8-97-127).

16. Lee Y.-H, Petkova A.P., Mottillo E.P., Granneman J.G. In vivo identification of bipotential adipocyte progenitors recruited by β3-adrenoceptor activation and high-fat feeding. Cell Metab. 2012;15(4):480–491. doi:10.1016/j.cmet.2012.03.009.

17. Merlin J., Evans B.A., Dehvari N., Sato M., Bengtsson T., Hutchinson D.S.1. Could burning fat start with a brite spark? Pharmacological and nutritional ways to promote thermogenesis. Mol Nutr Food Res. 2016;60(1):18–42. Doi: 10.1002/mnfr.201500251. Epub 2015 Aug 27.

18. Cypess A.M., Weiner L.S., Roberts-Toler C., Franquet Elía E., Kessler S.H., Kahn P.A., English J., Chatman K., Trauger S.A., Doria A., Kolodny G.M. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab. 2015;21(1):33–38. Doi: 10.1016/j.cmet.2014.12.009).

19. https://clinicaltrials.gov/ct2/show/NCT02919176

20. Fujimura T., Tamura K., Tsutsumi T., Yamamoto T., Nakamura K., Koibuchi Y. et al. Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;161:680–685.

21. Igawa Y., Yamazaki Y., Takeda H., Hayakawa K., Akahane M., Ajisawa Y. et al. Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126:819–825.

22. Takeda M., Obara K., Mizusawa T., Tomita Y., Arai K., Tsutsui T. et al. Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999;288:1367–1373.

23. Yamaguchi O. β3-Adrenoceptors in human detrusor muscle. Urology. 2002;59:25–29.

24. Nomiya M., Yamaguchi O. A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170:649–653.

25. Sjuve R., Boels P.J., Uvelius B., Arner A. Up-regulation of bradykinin response in rat and human bladder smooth muscle. J Urol. 2000;164:1757–1763.

26. Rapp D.E., Lyon M.B., Bales G.T., Cook S.P. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol. 2005;48:303–308.

27. Michel M.C., Ochodnicky P., Homma Y., Igawa Y. β-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacology Therapeutics. 2011;131(1):40–49. Doi:10.1016/j.pharmthera.2011.03.014.

28. Derweesh I.H., Wheeler M.A., Weiss R.M. Alterations in G-proteins and β-adrenergic responsive adenylyl cyclase in rat urinary bladder during ageing. J Pharmacol Exp Ther. 2000;294:969–974.

29. Ma F.H., Higashira-Hoshi H., Itoh Y. Functional muscarinic M2 and M3 receptors and β-adrenoceptors in cultured rat bladder smooth muscle. Life Sci. 2002;70:1159–1172.

30. Frazier E.P., Peters S.L.M., Braverman A.S., Ruggieri M.R., Sr., Michel M.C. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:449–462.

31. Ehlert F.J., Ahn S., Pak K.., Park G.J., Sangnil M.S., Tran J.A. et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder. J Pharmacol Exp Ther. 2007;322:631–637.

32. Klausner A.P., Rourke K.F., Miner A.S., Ratz P.H. Potentiation of carbacholinduced detrusor smooth muscle contractions by β-adrenoceptor activation. Eur J Pharmacol. 2009;606:191–198. Doi: 10.1016 / j.ejphar.2009.01.034.

33. Witte L.P.W., de Haas N., Mammen M., Stangeland E.L., Aiyar J., Michel M.C.Roles of M2 and M3 muscarinic receptors in the modulation of β-adrenoceptormediated relaxation of the rat urinary bladder. pA2 online 6, 2009. www.pA2online.org/ abstracts/Vol6Issue4abst053.pdf.

34. Michel M.C., Sand C. Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol. 2009;27:711–715. Doi: 10.1007 / s00345-009-0416-y.

35. Chapple C., Yamaguchi O., Ridder A., Liehne J., Carl S., Mattiasson A. et al. Clinical proof of concept study (Blossom) shows novel b3 adrenoceptor agonist YM 178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur. Urol. Suppl. 2008;7:239 (abstract 674).

36. Chapple C., Amarenco G., Lopez Aramburu M., Everaert K., Liehne J., Lucas M., et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32:1116–1122. doi: 10.1002 / nau.22373

37. Chapple C., Wyndae E.J., VanKerrebroeck P., Radziszewski P., Dvorak V., Boerrigter, P. Dose-ranging study of once-daily mirabegron (YMI 78), a novel selective 3-adrenoceptoragonist, in patients with overactive bladder (OAB). Eur. Urol. 2010;9:249.

38. Chapple C., Dvorak V., Radziszewski P., Van Kerrebroeck P., Wyndaele J., Bosman B., et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24:1447–1458. Doi: 10.1007/s00192-013-2042-x.

39. Nitti V., Flerschorn S., Auerbach S., Ayers M., Lee M., Martin, N. The selective

40. Nitti V., Auerbach S., Martin N., Calhoun A., Lee M., Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–1395. Doi: 10.1016 / j.juro.2012.10.017.

41. FDA (2012) Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 5 April 2012. Division of Reproductive and Urologic Products, Office of New Drugs Center for Drug Evaluation and Research of Food and Drug Administration. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Reproductive Health Drugs Advisory Committee/UCM298284.pdf (accessed 19 July 2012).

42. Chapple C., Kaplan S., Mitcheson H., Klecka J., Cummings J., Drogendijk T.et al. Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur Urol. 2012;Suppl 11:e683–e683a.

43. Chapple C., Kaplan S., Mitcheson D., Klecka J., Cummings J., Drogendijk T.et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305. Doi: 10.1016 / j.eururo.2012.10.048.

44. Khullar V., Cambronero J., Angulo J., Wooning M., Blauwet M., Dorrcpaal C., Martin N.E. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post-hoc analysis of a prospective, randomised European- Australian phase III trial. BMC Urol. 2013;13:45.

45. Khullar V., Amarenco G., Angulo J., Cambronero J., Høye K., Milsom I., et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295. Doi: 10.1016 / j.eururo.2012.10.016.

46. Kuo H., Lee K., Na Y., Sood R., Nakaji S., Kubota Y., et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2014;34:685–692. Doi: 10.1002 / nau.22645.

47. Yamaguchi O., Marui E., Kakizaki H., Homma Y., Igawa Y., Takeda M., et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 2014;113:951–960. Doi: 10.1111 / bju.12649.

48. Thiagamoorthy G., Kotes S., Zacchè M., Cardozo L. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder.Ther Adv Urol. 2016;8(1):38–46. Doi: 10.1177/1756287215614237.

49. Alexandre E.C., Kiguti L.R., Calmasini F.B., Silva F.H., da Silva K.P., Ferreira R. et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade. Br J Pharmacol. 2016;173:415–428. Doi: 10.1111 / bph.13367.

50. Calmasini F.B., Candido T.Z., Alexandre E.C., D’Ancona C.A., Silva D., de Oliveira M.A. et al. The β3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? Prostate. 2015;75:440–447. Doi: 10.1002 / pros.22930.

51. Martin C. Michel. How β3‐adrenoceptor‐selective is mirabegron? Br J Pharmacology. 2016;173(Issue 3):429–430. doi.org/10.1111/bph.13379.

52. Nitti V.W., Rosenberg S., Mitcheson D.H., et al. Urodynamics and safety of the 3-adrenoceptor agonist, mirabegron, in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013. Doi: pii: S0022–5347 (13) 04515–1. 10.1016/ j.juro.2013.05.062.

53. Germack R., Dickenson J.M. Induction of β3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. J Pharmacol Exp Ther. 2006;316:392–402.

54. Bundgaard H., Axelsson A., Hartvig Thomsen J., Sorgaard M., Kofoed K.F., Hasselbalch R. et al. The first-in-man randomized trial of a β3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail 2017;19:566–575. Doi: 10.1002 / ejhf.714.

55. https://clinicaltrials.gov/ct2/show/NCT02599480